-
Views
-
Cite
Cite
David Goldsmith, Adrian Covic, Marc Vervloet, Mario Cozzolino, Ionut Nistor, for the Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board, Mario Cozzolino, Mark Vervloet, Vincent Brandenburg, Jordi Bover, Adrian Covic, Pieter Evenepoel, David Goldsmith, Ziad Massy, Sandro Mazzaferro, Pablo Urena-Torres, D. Abramowicz, D. Bolignano, G. Cannata Andia, P. Cochat, A. Covic, L. Delvecchio, C. Drechsler, K.U. Eckardt, D. Fouque, J. Fox, M. Haller, O. Heimburger, K.J. Jager, E. Lindley, A.M. Marti Monros, E. Nagler, R. Oberbauer, G. Spasovski, J. Tattersall, W. Van Biesen, S. vander Veer, R. Vanholder, C. Wanner, D. Wheeler, W. Whithers, A. Wiecek, C. Zoccali, for the Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board, Should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement, Nephrology Dialysis Transplantation, Volume 30, Issue 5, May 2015, Pages 698–700, https://doi.org/10.1093/ndt/gfv050
- Share Icon Share
Abstract
This paper reflects the position of the CKD-MBD workgroup, an official working group of ERA-EDTA and of the ERBP advisory board, the official guideline-producing body of ERA-EDTA, on the topic of the use of calcimimetics in patients with CKD stage 5D, as based on two recent meta-analysis.
Comments